<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05063604</url>
  </required_header>
  <id_info>
    <org_study_id>HUB-PSI-CAMAD</org_study_id>
    <secondary_id>2019-004548-31</secondary_id>
    <nct_id>NCT05063604</nct_id>
  </id_info>
  <brief_title>Antidepressant Efficacy of Psychotherapy and Citalopram in Patients With Breast Cancer and Major Depression</brief_title>
  <acronym>CAMAD</acronym>
  <official_title>Randomized, Controlled, Open and Unicentric Phase II Clinical Trial, With Two Parallel Groups, to Evaluate the Antidepressant Efficacy of Psychotherapy and Citalopram in Women Diagnosed With Breast Cancer and Major Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitari de Bellvitge</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Catalan Institute of Oncology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Universitari de Bellvitge</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To provide evidence on the antidepressant efficacy of two therapeutic treatments:&#xD;
      pharmacological treatment (citalopram) and psychotherapy treatment, in women diagnosed with&#xD;
      breast cancer and major depression.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in severity of depression on the Beck Depression Inventory (BDI) at week 12.</measure>
    <time_frame>Every three weeks from baseline to the end of the study at week 12 (5 assessments in total).</time_frame>
    <description>The BDI is a validated, self-reported instrument assessing the severity of depression. Scoring range 0-9 indicates minimal depression, 10-18 mild depression, 19-29 moderate depression, and 30-63 severe depression.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in quality of life on the European Quality of Life Scale Five Dimensions and Three Levels (EQ-5D-3L) at week 12.</measure>
    <time_frame>Baseline and week 12.</time_frame>
    <description>The EQ-5D-3L is a standardized measure of health-related quality of life. The EQ-5D descriptive system comprises five dimensions with three levels of severity: 1 indicates no problems, 2 some problems, and 3 extreme problems.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in social-labor adaptation measured by number of days off work at week 12.</measure>
    <time_frame>Every three weeks from baseline to the end of the study at week 12 (5 assessments in total).</time_frame>
    <description>Number of days off work.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Age of patients.</measure>
    <time_frame>Baseline.</time_frame>
    <description>Measured in years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Marital status.</measure>
    <time_frame>Baseline.</time_frame>
    <description>Percentage of patients single, married, widowed, separated or divorced collected by a clinical interview.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cancer treatment received.</measure>
    <time_frame>Baseline.</time_frame>
    <description>Percentage of patients treated with surgery, radiotherapy, chemotherapy and/or hormonal therapy. This treatment information will be collected from the medical record.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Breast cancer stage.</measure>
    <time_frame>Baseline.</time_frame>
    <description>Breast cancer stage is expressed as a number on a scale from 0 to IV, where 0 describes non-invasive cancers that remain within their original location, and IV describes invasive cancers that have spread outside the breast to other parts of the body. This clinical information will be collected from the medical record.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Basal whole-brain activity by performing a functional Magnetic Resonance Imaging (fMRI).</measure>
    <time_frame>fMRI at baseline.</time_frame>
    <description>fMRI is a specialized form of magnetic resonance imaging used to examine regional brain activity, allowing the identification of the brain areas allegedly underpinning psychological processes. fMRI uses a specific imaging sequence (echo planar imaging) to measure small changes in blood oxygenation by assessing the so-called blood oxygenation level dependent (BOLD) signal over time, which is linked to regional neuronal function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in emotional processing on the Dot-Probe Task (DPT).</measure>
    <time_frame>DPT at baseline and week 12.</time_frame>
    <description>The DPT is a validated task to assess emotional processing by measuring reaction time to two types of stimuli (emotional face vs. neutral face), each one displayed on a different side of the screen. A faster reaction to emotional stimuli than to neutral ones indicates a bias of attention towards the emotional face and reflects dysfunction on emotional processing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-effectiveness ratio differences between pharmacological treatment with citalopram and psychological treatment in patients in our environment with breast cancer (BC) and major depression (MD).</measure>
    <time_frame>At week 12.</time_frame>
    <description>Analyze the cost of several variables, including both treatments (pharmacological and psychological), use of infrastructures and travel costs (only the first inclusion visit will be in person, the subsequent follow-up will be online).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and severity of secondary side effects related to the consumption of pharmacological treatment with citalopram according to the side effects rating scale Udvalg für Kliniske Undersogelser (UKU).</measure>
    <time_frame>At week 3, 6, 9 and 12.</time_frame>
    <description>The UKU side effects scale is designed to evaluate the secondary effects derived from the consumption of psychotropic drugs. The UKU scale comprises a total of 54 items that describe 54 side effects. Each item takes a value from 0 to 3 (0, no or doubtful present; 1, mild; 2, moderate; 3, severe).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Major Depressive Episode</condition>
  <arm_group>
    <arm_group_label>Citalopram 20-40 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received citalopram 20 mg tablet once or twice daily for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Psychotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received one psychotherapy session weekly for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Citalopram</intervention_name>
    <description>20 mg tablet one or twice daily for 12 weeks</description>
    <arm_group_label>Citalopram 20-40 mg</arm_group_label>
    <other_name>Prisdal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Psychotherapy</intervention_name>
    <description>One session weekly for 12 weeks</description>
    <arm_group_label>Psychotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female patients first time diagnosed with breast cancer (stage I, II, III, or IV)&#xD;
             between ages 18 and 75 (both inclusive).&#xD;
&#xD;
          -  Patients with a &quot;moderate-severe&quot; level of emotional distress who meet the diagnostic&#xD;
             criteria for major depression for at least two weeks or adjustment disorder with&#xD;
             depressive mood for at least two months, according to the Diagnostic and Statistical&#xD;
             Manual of Mental Disorders, Fifth Edition criteria (DSM-V), during the twelve months&#xD;
             following the diagnose of breast cancer.&#xD;
&#xD;
          -  Informed Consent Form Signature&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women who are pregnant or breastfeeding.&#xD;
&#xD;
          -  Suicide risk.&#xD;
&#xD;
          -  Metastatic brain disease.&#xD;
&#xD;
          -  Personal History of oncological disease.&#xD;
&#xD;
          -  Personal History of serious somatic disease (cardiac, hepatic, respiratory,&#xD;
             endocrinological, neurological and haematological).&#xD;
&#xD;
          -  Personal History of organic brain disorder, substance abuse/dependence.&#xD;
&#xD;
          -  Personal History of psychotic disorder, bipolar disorder and/or mental retardation.&#xD;
&#xD;
          -  Contraindications of citalopram treatment.&#xD;
&#xD;
          -  Taking antidepressants after the breast cancer diagnosis.&#xD;
&#xD;
          -  Psychotherapy treatment after breast cancer diagnosis .&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cinto Segalàs, MD, PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Psychiatrist at the Bellvitge University Hospital.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cinto Segalàs, MD, PhD.</last_name>
    <phone>0034932607922</phone>
    <email>csegalas@bellvitgehospital.cat</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maria Serra, Psych, PhD.</last_name>
    <phone>0034932607625</phone>
    <email>mariaserrab@iconcologia.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Catalan Institute of Oncology</name>
      <address>
        <city>L'Hospitalet De Llobregat</city>
        <state>Barcelona</state>
        <zip>08908</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cinto Segalàs, MD, PhD.</last_name>
      <phone>0034932607922</phone>
      <email>csegalas@bellvitgehospital.cat</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://cima.aemps.es/cima/pdfs/es/ft/60884/FT_60884.html.pd</url>
    <description>Citalopram technical data sheet.</description>
  </link>
  <results_reference>
    <citation>Fann JR, Thomas-Rich AM, Katon WJ, Cowley D, Pepping M, McGregor BA, Gralow J. Major depression after breast cancer: a review of epidemiology and treatment. Gen Hosp Psychiatry. 2008 Mar-Apr;30(2):112-26. doi: 10.1016/j.genhosppsych.2007.10.008. Review.</citation>
    <PMID>18291293</PMID>
  </results_reference>
  <results_reference>
    <citation>Vodermaier A, Linden W, Rnic K, Young SN, Ng A, Ditsch N, Olson R. Prospective associations of depression with survival: a population-based cohort study in patients with newly diagnosed breast cancer. Breast Cancer Res Treat. 2014 Jan;143(2):373-84. doi: 10.1007/s10549-013-2795-4. Epub 2013 Dec 13.</citation>
    <PMID>24337537</PMID>
  </results_reference>
  <results_reference>
    <citation>Miguel C, Albuquerque E. Drug interaction in psycho-oncology: antidepressants and antineoplastics. Pharmacology. 2011;88(5-6):333-9. doi: 10.1159/000334738. Epub 2011 Nov 26. Review.</citation>
    <PMID>22123153</PMID>
  </results_reference>
  <results_reference>
    <citation>Ochoa, C., &amp; Casellas-Grau, A. (2015). Positive Psychotherapy in Cancer: Facilitating Posttraumatic Growth in Assimilation and Accomodation of Traumatic Experience. In C.R. Martin, V. R. Preedy &amp; B. P.Vinood (Eds.). Comprehensive Guide to Post-Traumatic Stress Disorder (pp.113-127). Verna: Springer International Publishing Switzerland.</citation>
  </results_reference>
  <results_reference>
    <citation>Godlewska BR, Browning M, Norbury R, Igoumenou A, Cowen PJ, Harmer CJ. Predicting Treatment Response in Depression: The Role of Anterior Cingulate Cortex. Int J Neuropsychopharmacol. 2018 Nov 1;21(11):988-996. doi: 10.1093/ijnp/pyy069.</citation>
    <PMID>30124867</PMID>
  </results_reference>
  <results_reference>
    <citation>Victor TA, Furey ML, Fromm SJ, Ohman A, Drevets WC. Relationship between amygdala responses to masked faces and mood state and treatment in major depressive disorder. Arch Gen Psychiatry. 2010 Nov;67(11):1128-38. doi: 10.1001/archgenpsychiatry.2010.144.</citation>
    <PMID>21041614</PMID>
  </results_reference>
  <results_reference>
    <citation>Victor TA, Furey ML, Fromm SJ, Öhman A, Drevets WC. Changes in the neural correlates of implicit emotional face processing during antidepressant treatment in major depressive disorder. Int J Neuropsychopharmacol. 2013 Nov;16(10):2195-208. doi: 10.1017/S146114571300062X. Epub 2013 Jul 1.</citation>
    <PMID>23809145</PMID>
  </results_reference>
  <results_reference>
    <citation>Avis NE, Levine B, Naughton MJ, Case LD, Naftalis E, Van Zee KJ. Age-related longitudinal changes in depressive symptoms following breast cancer diagnosis and treatment. Breast Cancer Res Treat. 2013 May;139(1):199-206. doi: 10.1007/s10549-013-2513-2. Epub 2013 Apr 16.</citation>
    <PMID>23588951</PMID>
  </results_reference>
  <results_reference>
    <citation>BECK AT, WARD CH, MENDELSON M, MOCK J, ERBAUGH J. An inventory for measuring depression. Arch Gen Psychiatry. 1961 Jun;4:561-71.</citation>
    <PMID>13688369</PMID>
  </results_reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 27, 2021</study_first_submitted>
  <study_first_submitted_qc>September 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2021</study_first_posted>
  <last_update_submitted>September 21, 2021</last_update_submitted>
  <last_update_submitted_qc>September 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Universitari de Bellvitge</investigator_affiliation>
    <investigator_full_name>Cinto Segalàs Cosi, MD</investigator_full_name>
    <investigator_title>Psychiatrist at the Bellvitge University Hospital. Researcher at the Bellvitge Biomedical Research Institute (IDIBELL). Associate professor at the Clinical Sciences Department of the Barcelona University (UB).</investigator_title>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>Major Depressive Episode</keyword>
  <keyword>Antidepressant Efficacy</keyword>
  <keyword>Psychotherapy</keyword>
  <keyword>Citalopram</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citalopram</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 4, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/04/NCT05063604/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 14, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/04/NCT05063604/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

